DEFA14A ·Filed Apr 28, 2026

BIIB

BIOGEN INC.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001193125-26-187383
Proxy solicitation materials
Actionable Insight • Neutral

No trading action warranted. This is a routine proxy notice with standard proposals. Monitor the actual proxy statement for any compensation changes or governance updates that could affect shareholder voting.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
BIIB ▲ +3.23% at T+60d
NEUTRAL call ✓ call won +3.23% · α vs SPY -0.51% · entry $194.34 → $200.62
Entry anchored
Apr 28, 2026
via day open
T+1d
-2.57%
call -2.57% · α -3.59%
$189.35
settled 5mo ago
T+5d
-2.15%
call -2.15% · α -5.26%
$190.17
settled 5mo ago
T+20d
+0.78%
call +0.78% · α -5.27%
$195.86
settled 4mo ago
T+60d
+3.23%
call +3.23% · α -0.51%
$200.62
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Biogen filed a DEFA14A (additional definitive proxy soliciting materials) providing notice of its 2026 Annual Meeting to be held on June 9, 2026. The filing outlines standard proposals: election of 10 director nominees, ratification of PricewaterhouseCoopers as auditor, and an advisory vote on executive compensation. This is a routine administrative filing with no material financial information or activist campaign content.

Key Facts

  • Annual Meeting scheduled for June 9, 2026 at 9:00 AM ET, virtual format
  • Board recommends voting FOR all 10 director nominees
  • Board recommends voting FOR ratification of PricewaterhouseCoopers as auditor for FY2026
  • Board recommends voting FOR advisory say-on-pay proposal
  • Voting deadline is June 8, 2026 at 11:59 PM ET
  • Proxy materials include 2026 Notice and Proxy Statement and 2025 Annual Report/Form 10-K

Financial Impact

No financial figures disclosed in this filing

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
47% bullish (43 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-187383
Document: 0001193125-26-187383-index-headers.html0001193125-26-187383
Document: 0001193125-26-187383-index.html0001193125-26-187383
Document: 0001193125-26-187383.txt0001193125-26-187383
25 reports for BIIB
Performance horizon
92% Hit rate 12 of 13 directional calls best @ T+60▲ +11.76%Jun 8, 2026
Filters
Rows
Reports for BIIB — sortable, filterable
TypeNow
Sep 3, 2026
28d ago
Press Release
NEUTRAL ★ 4/10
$220.83 $217.36▼ −1.57%▼ −0.36%$219.88 (−0.43%)
Sep 3, 2026
29d ago
Press Release
BULLISH ★ 7/10
$224.51 $217.15▼ −3.28%▼ −2.13%$219.88 (−2.06%)
Aug 6, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$207.94 $209.83▲ +0.91%▲ +0.51%$219.88 (+5.74%)
Jul 14, 2026
11w ago
Press Release
BULLISH ★ 7/10
$191.95 $199.95▲ +4.17%▲ +5.46%$219.88 (+14.55%)
Jul 13, 2026
11w ago
Press Release
BULLISH ★ 6/10
$191.95 $199.95▲ +4.17%▲ +5.46%$219.88 (+14.55%)
Jul 13, 2026
11w ago
ANALYST-UPGRADE
BULLISH ★ 3/10
—awaiting T+5——
Jun 17, 2026
15w ago
Press Release
NEUTRAL ★ 4/10
$196.58 $201.96▲ +2.74%▲ +4.40%$219.88 (+11.85%)
Jun 8, 2026
16w ago
ANALYST-UPGRADE
BULLISH ★ 2/10
$192.62 $198.64▲ +3.13%▲ +1.01%$219.88 (+14.15%)
Jun 4, 2026
17w ago
Press Release
NEUTRAL ★ 5/10
$195.82 $199.96▲ +2.12%▲ +4.67%$219.88 (+12.29%)
Jun 1, 2026
17w ago
Press Release
MIXED ★ 5/10
$192.22 $195.34▲ +1.63%▲ +4.38%$219.88 (+14.39%)
Showing 10 of 25

US Market Status

Market Closed — Opens Mon (65h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access